Therapeutic Purpose and Mechanism

Эуфиллин (Aminophylline) is a bronchodilator medication used to manage conditions characterized by airflow obstruction. It belongs to the methylxanthine class of drugs and works primarily by relaxing the smooth muscles of the bronchial tubes. This action helps to widen the airways, facilitating easier breathing for individuals with chronic respiratory issues.

In addition to its effects on the lungs, the medication exerts a mild stimulatory effect on the respiratory center in the brain and can increase the strength of diaphragmatic contractions. It also possesses mild diuretic properties and can influence cardiovascular function by slightly increasing heart rate and cardiac output.

Main Uses

The medication is primarily indicated for the treatment and prevention of symptoms associated with reversible airway obstruction. These conditions include:

• Bronchial Asthma: It is used to manage persistent symptoms and prevent nocturnal asthma attacks by maintaining open airways over an extended period.
• Chronic Obstructive Pulmonary Disease (COPD): It helps alleviate chronic shortness of breath in patients with emphysema or chronic bronchitis.
• Status Asthmaticus: In clinical settings, specialized forms of the medication are used as part of intensive therapy for severe, acute asthma exacerbations that do not respond to initial treatments.

Key Benefits

When integrated into a broader treatment plan, the medication offers several therapeutic advantages for respiratory health:

• Airway Relaxation: By reducing bronchospasms, it decreases the work of breathing and improves oxygen exchange.
• Mucociliary Clearance: It may help improve the movement of mucus out of the respiratory tract, aiding in clearer airways.
• Respiratory Support: The strengthening of respiratory muscles can be particularly beneficial for patients with chronic weakness of the diaphragm.
• Vascular Effects: It helps reduce pulmonary vascular resistance, which can lower the pressure in the pulmonary circulation system.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Эуфиллин?

Contraindicated Populations (Must Not Use)

Эуфиллин (Aminophylline) is contraindicated in patients with a known hypersensitivity to the drug, theophylline, ethylenediamine, or any other methylxanthine compound. Use is strictly prohibited for individuals with a history of acute myocardial infarction, severe tachyarrhythmia, and active peptic ulcer disease, as stated in official regulatory documentation.

---

Restricted and Conditional Use

Eligibility is restricted for populations at high risk of toxicity due to altered drug clearance. Older adults and patients with hepatic impairment require cautious use and close monitoring. Conditional eligibility also applies to patients with congestive heart failure, severe hypertension, seizure disorders (epilepsy), and those experiencing febrile illnesses. Use is generally allowed for adults and children/adolescents under monitoring, while use in neonates is typically reserved for apnea of prematurity. Furthermore, safe use during pregnancy is not established through controlled studies, and the medicine is generally not recommended during lactation.

Interactions with other medicines and products

The interaction profile for Эуфиллин (Aminophylline), which is primarily metabolized as Theophylline, is chiefly governed by its reliance on the CYP1A2 enzyme in the liver. Officially documented interactions fall into two main categories: exposure alteration and pharmacodynamic effects.

Exposure-Altering Interactions (CYP1A2)

Co-administration with potent CYP1A2 inhibitors (e.g., Cimetidine, the antibiotics Ciprofloxacin and Fluvoxamine) is documented to significantly decrease Theophylline clearance. This inhibition leads directly to increased Theophylline plasma concentration and exposure, as described in regulatory documents. Conversely, substances acting as CYP1A2 inducers (e.g., Phenytoin, Rifampicin, Carbamazepine, and tobacco smoking) are officially documented to increase Theophylline clearance, resulting in reduced plasma concentration. These clearance changes are considered clinically significant and form the basis of many regulatory warnings.

Pharmacodynamic and Restriction Rules

Theophylline carries specific restrictions and documented pharmacodynamic effects. Co-administration is formally contraindicated with other xanthine derivatives due to the risk of additive toxic effects. Pharmacodynamic interactions include an increased risk of hypokalemia when combined with Beta-Adrenergic Agonists and an elevated risk of ventricular arrhythmias when used with Halothane anesthetic agents. Furthermore, Theophylline is documented to increase the renal clearance of Lithium. Regulatory information also notes that reduced Theophylline clearance in elderly patients and individuals with hepatic impairment can magnify the severity of inhibitory drug interactions, a key population-specific consideration.

The mechanism of action for Эуфиллин is defined by the active component, Theophylline, and its ability to modulate multiple biological targets simultaneously, primarily focusing on enzymes and receptors that regulate muscle tone and inflammation.

Modulation of Cyclic Nucleotide Signaling and Muscle Tone

This domain covers the drug's effect as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, which increases the concentration of intracellular messengers like cyclic AMP (cAMP). This molecular cascade leads to the resulting physiological effect of relaxation of smooth muscle tissue in the airways.

---

Antagonism of Adenosine Receptors

The drug acts as a competitive antagonist of Adenosine receptors (A1, A2B), preventing the binding of the endogenous nucleoside in various tissues. This interaction reduces the release of pro-constrictive and inflammatory mediators, influencing the level of physiological hyper-responsiveness and producing a systemic stimulatory effect.

---

Indirect Regulation of Inflammatory Gene Expression

This domain involves a distinct mechanism of enhancing the function of Histone Deacetylase 2 (HDAC2), often impaired by cellular redox changes, through the inhibition of PI3K-delta kinase. This cascade leads to a suppression of pro-inflammatory gene transcription within immune cells, leading to a modulation of pro-inflammatory gene transcription.

Эуфиллин (Aminophylline) is administered through distinct routes depending on the clinical context. For the treatment of acute respiratory distress, the primary method is intravenous (IV) infusion, which necessitates specialist supervision in a hospital setting. Oral administration, typically via tablets or solutions, is reserved for long-term or maintenance use.

IV dosing follows a strict two-phase regimen that must be precisely calculated. An initial, single Loading Dose is given, which must be infused slowly over 20 to 30 minutes, never exceeding the maximum rate of 25 mg per minute. This is immediately followed by a Continuous Maintenance Infusion. Crucially, all doses must be calculated using the patient’s Ideal Body Weight (IBW), rather than total body weight.

The maintenance infusion rate is individualized and subject to population-specific adjustments. For instance, older adults and patients with hepatic impairment require a substantially reduced maintenance dose. Conversely, children aged 6 months to 9 years typically require a higher rate. The entire treatment protocol mandates mandatory monitoring of serum theophylline concentrations to ensure the dose sustains the desired therapeutic level, and the infusion rate is adjusted accordingly. The IV solution must be diluted in a suitable fluid prior to administration.

Research evidence / Overview of studies for Эуфиллин

---

Evidence for use in Acute Asthma Exacerbation

Research has examined the use of Aminophylline (Эуфиллин) for conditions associated with acute or disruptive episodes, specifically severe asthma attacks. Studies explored whether adding this drug to standard, guideline-recommended therapies was associated with a difference in clinical outcomes. These short-term Randomized Controlled Trials (RCTs) monitored groups of adults, children, and adolescents experiencing unstable symptoms. Outcomes monitored included direct physical measurements of airway function (like FEV1 and PEFR) and key clinical markers like hospitalization rates and the total length of hospital stay.

For adults, research so far indicates that when the drug was studied for severe asthma, numerous studies described patterns where no consistent difference was observed in hospitalization rates or other key clinical outcomes when added to the current standard regimen. The findings were mixed when evaluating the immediate changes in breathing capacity. For children and adolescents, studies also explored this combination, with some research highlighting changes measured in functional outcomes related to airflow. However, other key clinical outcomes, such as the total time spent in the hospital, were observed in some studies to be no different.

The evidence is limited regarding clinical patterns when used routinely for adults with acute asthma. Since follow-up durations were limited to short-term observation (usually 48 hours or less), the long-term effects of using this medication during severe acute episodes are not fully established.

---

Evidence for use in Acute Exacerbation of COPD

Aminophylline was studied for conditions involving periods of heightened symptoms of Chronic Obstructive Pulmonary Disease (COPD) flare-ups. The research examined whether adding the drug to existing treatment regimens was associated with a difference in short-term measured outcomes. Studies conducted during periods of increased symptom activity included RCTs and Observational Studies that monitored adult patients during acute episodes.

Research observed patterns suggesting that core functional measures and the length of hospital stay often did not change when the drug was added to standard care. In small, specific patient groups presenting with refractory symptoms, some studies described patterns indicating changes in physiological strain or stress markers in the blood or subjective improvements in dyspnea severity. Overall, the data show patterns related to limited change in core clinical outcomes for routine use in this population.

Evidence quality varies across studies, and the sample sizes were modest in some of the most relevant trials. This means the certainty of benefit for routine use remains low. Furthermore, the results apply only to the populations studied, and the available data provides limited insight into long-term outcomes following an acute event.

Key Studies & References

1. Comparative observational study of aminophylline with prophylactic and therapeutic uses for clinical outcomes in preterm infants
2. Aminophylline: MedlinePlus Drug Information

Common questions about Эуфиллин (FAQ)

---

Q: How long after taking does Эуфиллин start to work?

According to official product information for the immediate-release oral form, the time it takes to reach peak concentration in the bloodstream (Tmax) is typically 1 to 2 hours after administration. This pharmacokinetic data describes the speed at which the medicine is absorbed into the body.

---

Q: What should I do if I miss a dose of Эуфиллин?

Official guidance notes that if a dose is missed, it should be discussed with the prescribing healthcare professional. If the next dose is due shortly, regulatory guidance suggests the missed dose may need to be skipped to avoid taking too much medication too close together. Official guidance recommends that a double dose not be taken to make up for a missed one.

---

Q: How long can Эуфиллин be taken?

Official documents indicate that the oral form of this medicine is reserved for long-term or maintenance use under physician supervision. For patients on long-term therapy, regulatory guidance recommends that blood concentrations of the active component be monitored periodically, usually every 6 to 12 months, to ensure optimal treatment levels are maintained.

---

Q: Are there age restrictions for taking Эуфиллин?

Official prescribing information states that the use of the intravenous formulation in children under 6 months of age is generally not recommended. This is due to the marked variability in how the medicine is processed (metabolized) in infants of this age group.

---

Q: Is a special diet necessary when taking Эуфиллин?

Regulatory documents indicate that taking the immediate-release form with food does not typically cause clinically significant changes to its absorption. However, official documentation notes that consuming large amounts of caffeine-containing foods or beverages should be avoided, as caffeine is similar to the medicine and can potentially increase central nervous system stimulation and side effects.

---

Q: Does Эуфиллин help with bronchitis?

Yes, official prescribing information lists this medicine as an adjunct treatment. Its uses include acute exacerbations of symptoms associated with reversible airflow obstruction in various chronic lung diseases, including chronic bronchitis.

---

Q: Does Эуфиллин have a diuretic effect?

Pharmacological texts describe that the active component, theophylline, possesses effects that include diuresis, which means an increase in urine production. This is considered a known clinical effect of the methylxanthine class of drugs.

---

Q: How does an allergy to Эуфиллин manifest?

Official patient safety information lists potential signs of allergic reaction. These may include the development of a skin rash, itching, hives, or swelling of the face, lips, tongue, or throat. In severe cases, difficulty breathing is noted as a possibility.

---

Q: Is it safe to take Эуфиллин in old age?

Official safety information notes that the medicine should be administered with caution in older adults, such as those over 55 years of age. This is related to reduced drug clearance in this population, which increases the potential for side effects and is often addressed by dose adjustment protocols.

---

Q: What tests need to be taken during long-term treatment with Эуфиллин?

Regulatory guidance emphasizes the mandatory monitoring of serum theophylline concentrations, which is the amount of medicine in the blood, to ensure the dose is within the therapeutic range. Furthermore, plasma potassium levels may need to be checked periodically in individuals considered at risk, for example, those taking other specific medications concurrently.

---

Q: Why is Эуфиллин sometimes prescribed for pathologies in newborns?

The active component, Theophylline, is described as a methylxanthine that acts as a central respiratory stimulant. The use of this drug in neonates is typically reserved for a condition known as apnea of prematurity (AOP), where it is used to help stimulate breathing.

---

Q: How do I know if Эуфиллин is right for me and is working?

The drug's primary physiological action is described as the relaxation of the smooth muscle in the airways, which is intended to facilitate easier breathing. The determination of whether the drug is working relies on the prescribing physician’s evaluation of clinical outcomes. This includes reviewing symptoms alongside mandatory monitoring of the drug's concentrations in the blood.

---

Q: Can Эуфиллин be taken if there are stomach problems?

Official safety information advises caution for use in individuals with conditions such as peptic ulcer disease or other pre-existing stomach or intestinal problems. Gastrointestinal side effects like nausea and vomiting are also commonly listed in the adverse effects profile.

---

Q: What could 'mood swings' be related to when taking Эуфиллин?

Regulatory documents list adverse effects on the Nervous System, including restlessness and irritability. Mood changes have also been noted in official documents as potential signs of toxicity or overdose, which are typically associated with high blood concentrations of the drug.

---

Q: What are the main indications for prescribing Эуфиллин?

The main regulatory uses are described as an adjunct treatment for acute exacerbations of symptoms associated with reversible airflow obstruction. These conditions include asthma and other chronic lung diseases such as emphysema and chronic bronchitis.

---

Q: Is it true that Эуфиллин can affect sleep?

Yes, official documents list insomnia and sleeplessness as common adverse effects categorized under nervous system disorders. These effects are consistent with the drug's systemic stimulatory action.

---

Q: What forms of Эуфиллин exist (besides tablets and injections)?

According to official sources, the medicine is available in various forms. In addition to injectable solutions (IV/IM) and oral tablets, it is also available as a syrup and suppositories.

---

Q: What side effects of Эуфиллин can occur in children?

Official safety information notes that children, particularly those under 1 year of age, are more susceptible to serious side effects. They may experience increased tachycardia (rapid heart rate) and gastrointestinal effects compared to other age groups.

How to Store and Dispose of Эуфиллин (Aminophylline/Theophylline)

Official labeling requires Эуфиллин (Aminophylline/Theophylline) to be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted brief excursions up to 30 C. The product must be kept in its original container, be tightly closed, and must not be frozen.

For safety, the medication must be stored out of the sight and reach of children.

Aminophylline Injection is a single-dose product, and any unused portion must be immediately discarded.

Disposal of expired or unused medicine should prioritize drug take-back programs. If these are unavailable, the medicine must be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container for disposal in household trash. The product is not recommended for flushing.